Vitamin D deficiency Chronic Hepatitis C T-
Conditions
Interventions
The dosages of ergocalciferol or vitamin D2 supplement were given according to our protocol based on the ranges of vitamin D deficiency as following: for mild deficiency (20 to less than 30 ng/mL) 60
000 unit/week,
for moderate deficiency (10 to less than 20 ng/mL) 80,
and for severe deficiency (less than 10 ng/mL) 10,
000 unit/week. Each vitamin D2 capsule contained 20,
000 units. The total dosage was divided into 2 separate doses giving on Monday and Friday.,The placebo and vitamin D2 capsules were made resemble and have the same weight.
Experimental Drug,Placebo Comparator Drug
Sponsors
No
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Thai male or female, aged 18-70 years old. 2. Chronic hepatitis C which was diagnosed more than 6 months. - Albumin > 3.4 mg/dl - Total bilirubin 75,000 3. Compensated liver cirrhosis. 4. Consent for participation. 5. Serum 25 OH vitamin D level < 30 ng/ml.
Exclusion criteria
Exclusion criteria: 1. Underlying disease(s) ; Human Immunodeficiency virus (HIV) infection, autoimmune disease. 2. Decompensated Liver Cirrhosis. 3. Pregnancy and/or lactating women. 4. Active viral or bacterial infection. 5. History of steroids or immunosuppressive therapy 6. No history of Pegylated interferons and interferons based therapies, interferons withdrawal at least 6 months, ingestion of drugs potentially capable of interacting with immune system
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| T-Helper1/2 cytokines levels 6 weeks Cytokine quantitation was performed on bead-based ELISA | — |
Secondary
| Measure | Time frame |
|---|---|
| IP-10,DPP-4 levels 6 weeks quantitative sandwich enzyme immunoassay technique | — |
Countries
Thailand
Contacts
Public ContactPiyawat Komolmit
MD, M.Sc.
Outcome results
None listed